Skip to main
SPTX

SPTX Stock Forecast & Price Target

SPTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Seaport Therapeutics is poised for success with a strong pipeline and promising clinical trials, backed by a large investment and experienced leadership in the form of Dr. Loebel. However, the incident with the dog raises concerns about potential side effects that may need to be addressed in further trials. Sunovion's two successful drugs also provide competition in the market, which may impact Seaport's market share and stock price in the future.

Bears say

Seaport Therapeutics is a relatively young company with a lack of operating history, rendering it difficult to accurately evaluate their business. The company's main pipeline products are based on its proprietary Glyph platform, which aims to enhance drug's oral bioavailability and reduce side effects. However, clinical data from the company's lead candidates and key figures should be taken with caution, as they are still in early development stages. Furthermore, there are significant risks associated with investing in the company, including clinical, regulatory, commercial, and dilution of equity.

SPTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seaport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seaport Therapeutics Inc (SPTX) Forecast

Analysts have given SPTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, SPTX has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seaport Therapeutics Inc (SPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.